Megha Manchanda &Amp;Amp; Sohini Das

Stories by Megha Manchanda &Amp;Amp; Sohini Das

Bharat Biotech starts Covaxin's at-risk manufacture

Bharat Biotech starts Covaxin's at-risk manufacture

Rediff.com   2 Nov 2020

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Why Nitin Gadkari is angry with Highway Authority

Why Nitin Gadkari is angry with Highway Authority

Rediff.com   30 Oct 2020

At the heart of his criticism is the delay in decision making and a lack of monitoring. Some officials, however, blamed the delays on overambitious contractors.

Bharti Airtel to stay away from 5G auctions

Bharti Airtel to stay away from 5G auctions

Rediff.com   29 Oct 2020

Airtel CEO said, the 5G ecosystem is yet to develop in India and the prices are very high. Telecom companies including Vodafone Idea (VI) and Reliance Jio have also said that the current prices are exorbitant.

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com   25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

Covid-19 impact: Low interest loans likely for vaccine companies

Covid-19 impact: Low interest loans likely for vaccine companies

Rediff.com   10 Oct 2020

While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.

Covaxin: How Bharat Biotech plans to boost immunity

Covaxin: How Bharat Biotech plans to boost immunity

Rediff.com   6 Oct 2020

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed.

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Rediff.com   6 Oct 2020

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.

Covid vaccine: Pharma firms ready expansion plans

Covid vaccine: Pharma firms ready expansion plans

Rediff.com   6 Oct 2020

The Indian vaccine industry largely feels there are two ways in which vaccine innovation can be spurred - one, get a high price for the product and two, have the government buy a few hundred million doses of the product at a certain price.

Vodafone Plc's arbitration win: Should India challenge the decision?

Vodafone Plc's arbitration win: Should India challenge the decision?

Rediff.com   5 Oct 2020

The arbitration of any court is legally binding and the government) can approach the Singapore high court.

How India is gearing up to distribute Covid-19 vaccine

How India is gearing up to distribute Covid-19 vaccine

Rediff.com   18 Sep 2020

A model being considered is to have a combined cold chain approach - where the agricultural cold chain would be combined with vaccine cold chains.

Labs bet on Covid tests for next growth phase

Labs bet on Covid tests for next growth phase

Rediff.com   14 Sep 2020

The bouquet of Covid-19 tests that most diagnostic labs are offering include antibody tests (blood tests), rapid antigen tests (point of care tests that detect the presence of an antigen from a nasal or throat swab in case of SARS-CoV-2), and reverse transcription-polymerase chain reaction (RT-PCR) tests.

Govt plans to build Zojila-like tunnel to Ladakh

Govt plans to build Zojila-like tunnel to Ladakh

Rediff.com   14 Sep 2020

The tunnel would reduce the travel time to the Ladakh region by 15-20 per cent and would come up close to the Atal tunnel near Rohtang Pass, reports Megha Manchanda.

India will wait for DCGI nod to restart Oxford vaccine trial

India will wait for DCGI nod to restart Oxford vaccine trial

Rediff.com   11 Sep 2020

The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.

With coronavirus still around, 'virus killers' hit the market

With coronavirus still around, 'virus killers' hit the market

Rediff.com   7 Sep 2020

A gamechanger for offices and factories, Shycocan, claims to be able to clear an area of 1000 square feet from coronavirus.

In the works: Priority list of who will get Covid vaccine first

In the works: Priority list of who will get Covid vaccine first

Rediff.com   4 Sep 2020

The Centre has also contacted five domestic and three multinational vaccine makers to understand how soon a candidate vaccine against Covid-19 will be ready.

Indian pharma firms working on new repurposed drug for Covid-19

Indian pharma firms working on new repurposed drug for Covid-19

Rediff.com   2 Sep 2020

Many companies globally are working on plasma research to develop and manufacture hyperimmune globulin therapies from plasma donations.

Vodafone Idea's future hinges on SC's AGR verdict

Vodafone Idea's future hinges on SC's AGR verdict

Rediff.com   31 Aug 2020

If the apex court decides on a 15-year repayment tenure, it would pose a grave challenge for the debt ridden VIL.

Covid-19: Airtel, Vodafone Idea not as lucky as Reliance Jio

Covid-19: Airtel, Vodafone Idea not as lucky as Reliance Jio

Rediff.com   27 Aug 2020

While Reliance Jio added 3.65 million users in May, both Bharti Airtel and Vodafone Idea continued to lose subscribers.

Pandemic brings windfall for e-pharma companies

Pandemic brings windfall for e-pharma companies

Rediff.com   27 Aug 2020

The online pharmacy market, which was worth about $512 million in 2018, is growing at a CAGR of 63 per cent and is expected to hit overall revenues of over $3.6 billion by 2022.

How India's healthcare system will change forever

How India's healthcare system will change forever

Rediff.com   27 Aug 2020

The National Digital Health Mission seeks to provide a unique health ID to each citizen who wishes to have one and also on-board the healthcare service provides - hospitals, pharmacies and diagnostic labs, among others. It will have an online database of doctors and personal health records.